Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020117526 - IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Publication Number WO/2020/117526
Publication Date 11.06.2020
International Application No. PCT/US2019/063024
International Filing Date 25.11.2019
IPC
C07K 16/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 14/54 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
C12N 5/078 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/7056
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
7056Lectin superfamily, e.g. CD23, CD72
Applicants
  • FATE THERAPEUTICS, INC. [US]/[US]
Inventors
  • VALAMEHR, Bahram
  • BJORDAHL, Ryan
  • LEE, Tom, Tong
Agents
  • FORCE, Walker
  • ALLISON, Wiiliam, F.
  • ADAMS, Lisa
  • AZRIN, Linda, B.
  • AMENDT, Kevin, C.
Priority Data
62/774,27802.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
(FR) IMMUNOTHÉRAPIES UTILISANT DES CELLULES EFFECTRICES DÉRIVÉES DE IPSC AMÉLIORÉES
Abstract
(EN)
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
(FR)
La présente invention concerne des procédés et des compositions permettant d'obtenir des cellules effectrices dérivées fonctionnellement améliorées obtenues à partir de la différenciation dirigée d’iPSC à génome modifié. La présente invention concerne des cellules dérivées présentant une édition stable et fonctionnelle du génome qui fournit des effets thérapeutiques améliorés ou renforcés. La présente invention concerne également des compositions thérapeutiques et leur utilisation comprenant des cellules effectrices dérivées fonctionnellement améliorées seules, ou avec des anticorps ou des inhibiteurs de point de contrôle dans des polythérapies.
Latest bibliographic data on file with the International Bureau